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Abstract: Multimodal spectral histopathology (MSH), an optical technique 
combining tissue auto-fluorescence (AF) imaging and Raman micro-
spectroscopy (RMS), was previously proposed for detection of residual 
basal cell carcinoma (BCC) at the surface of surgically-resected skin tissue. 
Here we report the development of a fully-automated prototype instrument 
based on MSH designed to be used in the clinic and operated by a non-
specialist spectroscopy user. The algorithms for the AF image processing 
and Raman spectroscopy classification had been first optimised on a 
manually-operated laboratory instrument and then validated on the 
automated prototype using skin samples from independent patients. We 
present results on a range of skin samples excised during Mohs 
micrographic surgery, and demonstrate consistent diagnosis obtained in 
repeat test measurement, in agreement with the reference histopathology 
diagnosis. We also show that the prototype instrument can be operated by 
clinical users (a skin surgeon and a core medical trainee, after only 1-8 
hours of training) to obtain consistent results in agreement with 
histopathology. The development of the new automated prototype and 
demonstration of inter-instrument transferability of the diagnosis models are 
important steps on the clinical translation path: it allows the testing of the 
MSH technology in a relevant clinical environment in order to evaluate its 
performance on a sufficiently large number of patients.  
©2017 Optical Society of America  
OCIS codes: Medical optics and biotechnology; Medical and biological imaging; Medical 
optics and biotechnology; Spectroscopy, Raman. 
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1. Introduction  
Basal cell carcinoma (BCC) is the most common cancer type in humans. More than 
100,000 cases of BCC are diagnosed each year in the UK (1.7 million in the USA, and 
300,000 in Australia) [1]. Patients expect their BCCs to be treated effectively in a single 
operation, with minimal risk of tumor recurrence, and the best cosmetic result possible. Most 
BCCs (>80%) occur on the head and neck areas, in particular the upper central part of the face 
[2]. The majority of these BCCs are treated by wide-local excision performed under local 
anesthesia in an outpatient setting. The treatment outcome of wide-local excision depends on 
the characteristics of the tumor (subtype, location), as well as how well the surgeon can 
identify its spread. For example, a 4 mm surgical margin for primary well-defined BCC 
measuring less than 20mm ensures a complete clearance of over 95% [3] while a 3mm 
margin, even for lesions that measure 6×5 mm, will clear only about 85% of tumors [4,5]. 
Large BCCs (>2cm) and those occurring at high risk sites (nose, ear, eyelid, eyebrow, and 
temple) are at higher risk of incomplete treatment, and Mohs micrographic surgery is 
preferred [6-8]. In Mohs surgery, sequential layers of tissue are excised and microscopically 
examined as frozen sections to make sure that all cancer is removed; if residual cancer is 
present, then the exact location of those cells is recorded and further layers of skin tissue are 
removed until margins are clear. Although wide-local excision is the most common surgical 
technique for treating BCC, histopathological confirmation of complete removal takes 1-2 
weeks. Incomplete removal requires specialist follow-up or a second operation to remove the 
residual cancer (typically by Mohs surgery), which can lead to patient anxiety and poorer 
cosmetic outcome, especially if a skin graft from the initial treatment needs to be redone. 
Although Mohs surgery is typically recommended for high-risk BCCs [9], this complex 
surgery requires specialist surgeon and treatment facilities, and is labor intensive, needing 
dedicated technicians to prepare frozen tissue sections.  
Several technologies have been developed recently to allow microscopic assessment of 
tumor clearance during BCC surgery, including confocal microscopy (CM) [10,11], optical 
coherence tomography (OCT) [12,13] and Raman micro-spectroscopy [14]. While CM and 
OCT enable diagnosis of BCC based on structural features, Raman spectroscopy can measure 
endogenous molecular differences between healthy skin tissue and BCC, with high chemical 
specificity [14-18]. Therefore, Raman spectroscopy offers the prospect of objective diagnosis 
based on quantitative molecular analysis of tissue, which has the potential to reduce intra- and 
inter-user variability, as well as diagnosis subjectivity [19, 20]. Although Raman spectroscopy 
is typically slow to allow imaging of cm-scale tissue samples within time-scales compatible 
with intra-operative use (e.g. <1 hour), selective-sampling Raman spectroscopy techniques 
have been recently developed to reduce measurement time [14, 21]. Our team has developed a 
multimodal spectral imaging technique that integrates tissue auto-fluorescence imaging and 
Raman microscopy that can be used during tissue conserving surgery for fast and objective 
detection of residual tumor [14, 22-24]. Using laboratory instruments, that partially included 
input from user (manual focusing and change of objectives when switching between auto-
fluorescence and Raman modalities), previous studies demonstrated the feasibility to obtain 
quantitative diagnosis images based on molecular analysis of tissue combined with 
multivariate classification models.  
Here, we report the development of a fully-automated prototype instrument based on the 
combined auto-fluorescence (AF) and Raman micro-spectroscopy (RMS) multimodal 
approach, that allows fully automated measurements of skin surgical resections and objective 
diagnosis of residual BCC. The instrument has been designed and built to fit into clinical 
practice as an alternative to current practice of microscopic histological assessment of frozen 
tissue sections for checking the completeness of BCC removal during all BCC surgery. First, 
we show that the optimized algorithms for analysis of the AF images and Raman 
classification models developed on a laboratory instrument can be successfully transferred on 
the fully automated new device. This is an important step because inter-instrument 
transferability remains one of the key challenges in the clinical translation of Raman 
spectroscopy. Secondly, we present a model for establishing a threshold based the MSH 
diagnosis image that allows a binary diagnosis at a tissue sample level: margins clear of BCC 
detected: Yes/No. Finally, we investigated the consistency and validity of the MSH diagnosis 
by comparing the MSH assessment output in repeat test measurements recorded by a 
spectroscopy specialist user and clinical users (Mohs surgeon and medical trainee), on a range 
of skin samples excised during Mohs micrographic surgery, and using histopathology as the 
standard of reference.  
2. Methods 
2.1 Tissue samples 
Skin tissue samples were obtained during Mohs micrographic surgery at the Nottingham 
University Hospitals National Health Service (NHS) Trust and the Nottingham NHS 
Treatment Centre. Ethical approval was granted by the Nottingham Research Ethics 
Committee (07/H0408/172) and informed consent was obtained from all patients. After 
excision by the surgeon, the tissue layer was embedded within optimal cutting temperature 
medium (OCT) and frozen with a cryogenic spray (Frostbite, Surgipath). For each tissue 
sample, a 10 μm section (called adjacent section) was cut and stained by hematoxilin and 
eosin (H&E) and used as the standard of reference. The remaining tissue block was then 
defrosted, washed and kept frozen at -20˚C until used for Raman spectral measurements. 
In this study, samples from 80 patients with basal cell carcinoma on the face and neck 
were included. The sample set was divided into a training set (50 samples, 30 patients) that 
was measured on the Laboratory Instrument in order to train and optimize the diagnosis 
algorithms. All the samples in the training set were used for the training of the Raman 
classification model, but only the BCC positive samples (35 samples, 23 patients) were used 
for optimization of the algorithms for AF image segmentation and sampling points generation. 
The test set consisted of 47 samples from new 40 patients, which were measured on the 
Prototype instrument to determine the performance of the algorithms. As with the samples 
recorded with the Laboratory Instrument, all test samples were used in the testing of Raman 
classification model, while only the BCC positive samples were used to validate the AF 
algorithms (32 samples, 27 patients). Then, 10 samples (9 patients, no overlap with the 
training or test sets) were used to test the overall performance of the MSH diagnosis on the 
Prototype device, including illustration of intra- and inter-user repeatability. 
2.2 Instrumentation  
Laboratory Instrument. The instrument consisted of an inverted optical microscope 
(Eclipse-Ti Nikon) with an automated sample stage (H107 with Proscan II controller, Prior 
Scientific), 60×/1.2NA objective (RiverD International), 785nm laser (IPS, power 100 mW at 
sample surface), spectrometer (RiverD International HPR) equipped with a deep-depletion 
back-illuminated cooled CCD (DU401-A-BR-DD, Andor Technology). The acquisition time 
for the Raman measurements ranged between 0.5 and 3 seconds per position.  
Prototype instrument. The instrument was developed jointly by University of Nottingham 
and RiverD International. The requirements and specifications for the clinical application 
were established through consultation with 3 general dermatologists, 23 skin surgeons 
(including Mohs and plastic surgeons) and 4 histopathologists. Its operation at all analysis 
steps was fully automated (see Fig.1(b,c)). The instrument was designed to analyse skin 
specimens of up to 2cm × 2cm in size (thickness up to 5mm), which would accommodate the 
whole excision surface of most resection specimens in Mohs surgery (including simultaneous 
analysis of up to 4 skin samples fitting the 2cm × 2cm area). The samples used in this study 
represented halves or quarters of spare skin samples resected during Mohs surgery. The 
samples were placed in purpose-designed disposable cassettes. After loading of the cassette in 
the instrument, a colour image of the sample is displayed on the screen to confirm the correct 
position of the tissue samples and to allow the user to identify the red and blue dye markings 
used for orientation of the tissue with respect to the surgical opening. The software included 
automated calibration, quality control checks and autofocusing of the Raman measurements. 
After the input of the required patient data, the user can start the analysis of the tissue by 
selecting the “Start” button. No additional input is required from the user to reach the final 
diagnosis. The software provides real time display of the AF images and presents the final 
MSH diagnosis as a colour-coded image. 
2.3 Data post-processing and analysis 
Auto-fluorescence imaging: Auto-fluorescence images of the tissue samples were acquired by 
stitching 16 image tiles (6.4mm x 6.4mm) to create a 2cm × 2cm image. The region of the 
image containing tissue was identified automatically and separated from the background by 
using a set intensity threshold. The AF image was then flattened with a rotationally symmetric 
Gaussian low pass filter to minimize fluctuations in intensity and stitching artefacts. The 
segmentation of the resulting AF image was then performed using an intensity thresholding 
based on the optimization described in Section 3. 
Raman spectroscopy. All Raman spectra were corrected for cosmic rays and were calibrated 
using a neon-argon light source and a PMMA sample, and corrected for the wavelength 
dependent sensitivity of the set up using a NIST calibration standard. Background signals 
from optical elements in the instrument were subtracted from the spectra. Spectra were then 
interpolated in the range of 400-1800 cm-1 to 2 cm-1 data spacing. For the training dataset, 
raster scans were performed on the surface of the removed tissue samples, adjacent to the 
H&E section. Spectra were acquired with a 0.5 s exposure time and were averaged with a 3x3 
moving average filter. Spectra were utilized in the classification model only if their signal to 
noise ratio (SNR) was above 15, where SNR was calculated as the ratio between the height of 
the CH2 peak at 1450 cm-1 (local linear baseline subtracted) and rms value of the noise in the 
empty spectral region 1750-1800 cm-1. For the test set, the Raman spectra were acquired with 
the Prototype instrument with a modified version of the MSH procedure that allowed 
acquisition of a larger number of spectra for each sample. To maximize the number of Raman 
spectra to be included in the test set, the minimum number of spectra per segment was 
increased to 20 and the total number of spectra acquired per tissue sample was limited to 
1200. The integration time was set to 3 s per spectrum and spectra with SNR lower than 7 
were discarded. Spectral features (areas of Raman bands) were calculated from the Raman 
spectra of both training and test samples using a local linear background subtraction for each 
band, and were then the normalized to unit norm on a per spectrum basis. 
2.4 MSH diagnosis 
The MSH algorithm generated the diagnosis of each segment obtained by the AF 
segmentation algorithm independently using the Raman spectra measured inside the segment 
in an automated two-step process. In the first round, Raman spectra were measured at the 
locations determined by the sampling point generation algorithm (spectra with SNR lower 
than 4 were discarded). More sampling points were generated to allow new Raman spectra to 
be measured in the second stage of the MSH procedure, to replace the spectra that are 
discarded. Segments for which more than 80% of the spectra were discarded, were labelled 
“Unclassified” (no more spectra were measured for these segments in the second round). The 
retained spectra were denoised based on an independent set of Raman spectra (100,000 
spectra collected from samples in the training set that were not included in the training set 
because the SNR was between 10-15) using principal component analysis (PCA) with 50 PCs 
[25]. Then, each Raman spectrum was classified by applying the Raman classification model. 
If the segment contained no spectra classified as BCC and the class of all spectra was the 
same, the segment was labelled accordingly. In cases in which the segment contained spectra 
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 3.1 Optimisation of the measurement and diagnosis algorithms based on the Laboratory 
Instrument 
In order to achieve reliable and objective diagnosis of BCC, the complete workflow (Fig. 
1(b)) must be invariant across the range of samples obtained in BCC surgery, and be 
transferable between instruments. In this way, once the algorithms have been optimised on 
one device, they can be transferred to all devices deployed in clinics. Thus, every step in the 
diagnosis workflow described in Fig. 1(b) was first optimised using a training set of samples 
analysed on the Laboratory instrument, for which the user was able to manually adjust the 
focusing and changing the objectives when switching between the AF and Raman 
measurements (Fig. 1(c) left). The algorithms were then tested using a new set of independent 
skin samples analysed on a fully automated Prototype, for which the user operation required 
only the loading of the tissue specimen. 
3.1.1 Segmentation algorithms for the auto-fluorescence imaging 
After the acquisition of the AF image of a skin sample, the entire image was segmented using 
an intensity threshold. However, because the AF images exhibit large inter-sample variations 
in intensity (caused by inter-patient variations in tissue depending on age, anatomic location, 
or pathology, potential laser intensity fluctuations), we developed a user-independent 
algorithm that optimises the value of the intensity threshold for each individual image. To 
quantify the performance of this algorithm, two metrics were defined: 
ߩ = ܣݎ݁ܽ(݀݁ݐ݁ܿݐ݁݀	ܤܥܥ)ܣݎ݁ܽ(݀݁ݐ݁ܿݐ݁݀	ܤܥܥ) + ܣݎ݁ܽ(݉݅ݏݏ݁݀	ܤܥܥ) 
This metric was calculated for all BCC positive samples in order to measure the fraction of 
the tumour detected and retained by the segmented AF image. 
ߝ = ܣݎ݁ܽ	(ܪ݈݁ܽݐℎݕ	ݐ݅ݏݏݑ݁)ܣݎ݁ܽ	(݀݁ݐ݁ܿݐ݁݀	ܤܥܥ) + ܣݎ݁ܽ	(ܪ݈݁ܽݐℎݕ	ݐ݅ݏݏݑ݁) 
The metric ε was calculated for each segment in an AF image containing BCC in order to 
estimate the histological heterogeneity of the segments. The values of Area(detected BCC), 
Area(missed BCC) and Area(Healthy tissue) were obtained by comparing the generated 
segmentation maps with the AF annotated images (manually marking the BCC regions on the 
AF images based on the adjacent H&E sections). Based on a set of comparable adjacent H&E 
sections, we estimate that the use of adjacent H&E sections for the annotation can lead to 
errors of ~10-100μm because of differences in tumour morphology between the tissue 
analysed by AF and the H&E sections. Thus, ߩ and ߝ are not an absolute measure of the 
performance of the segmentation algorithm to detect BCC, but rather offer an indication of 
how different methods of segmentation perform comparatively. 
For an ideal segmentation algorithm, the entire tumour is retained for Raman 
spectroscopy analysis, Area(missedBCC)=0, equivalent to ߩ = 1. In addition, all segments 
containing BCC would not contain any healthy tissue, Area(Healthy)=0, equivalent to ߝ = 0. 
Figure 2 presents some examples of segmentation results for typical skin tissue samples 
containing infiltrative and micro-nodular BCC. Figure 2(a) shows that the tumour regions 
have lower AF intensity compared to the stroma. Two functions were proposed for providing 
optimal segmentation thresholds invariant to the absolute intensity of the AF images: fA=N, 
where N is the number of segments in the segmented image, fB=N*A, where A is area fraction 
captured by the segments in the image. Figure 2(b) shows that both functions fA and fB have a 
global maximum when plotted as a function of the intensity threshold. Figure 2(c) presents the 
segmented AF images when the threshold used corresponded to the maximum values of 
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Fig. 5. Development of the Raman classification model for BCC. a) Average Raman spectra of 
BCC, healthy skin tissue structures and surgical dye. The spectral features selected for the 
ANN classifier are highlighted (red lines represent the local baseline); b) confusion matrix for 
the 5-fold cross validation on the training set of samples measured on the Laboratory 
instrument. Class EMI includes epidermis, muscle and inflammation. 
 
The spectral features used as the input for the classification models were calculated as the 
areas of selected Raman bands that provided stable classification of BCC: 675 cm-1, 680 cm-1, 
786 cm-1, 870 cm-1, 906 cm-1, 944 cm-1, 952 cm-1, 1092 cm-1, 1144 cm-1, 1298 cm-1, 1376 cm-1, 
1528 cm-1, 1744 cm-1. The confusion matrix obtained by 5-fold cross-validation (Fig. 5(b)) 
indicates that BCC can be discriminated from all other tissue types with overall 87.7% 
sensitivity and 98.4% specificity. Whilst the classification model obtained > 98.7% sensitivity 
and specificity for dermis and fat, it correctly distinguished BCC from the EMI class 
(epidermis, inflammation and muscle) in ~89.2% of spectra. 
3.1.3 Criterion for MSH diagnosis at sample level 
Based on the estimated performance of the AF imaging analysis algorithms and the Raman 
spectroscopy classifier, as well as on certain simplifying assumptions (see below), we 
investigated the statistically optimal criterion (uniformly most powerful test) for deciding if a 
sample is BCC positive or negative. Namely, given a threshold Nth on the number NBCC of 
BCC-labeled segments in the MSH diagnosis image, the criterion is to call the sample “BCC-
positive” if NBCC≥Nth, and “BCC-negative” otherwise (i.e. if NBCC<Nth). To derive the 
necessary expressions we simplified the two-round rule for labelling a segment as follows: a 
segment is labelled as BCC if and only if at least two spectra are (individually) classified as 
BCC. Similarly, we assumed the number of Raman spectra per segment Nsampling(i) to be the 
same for all segments and equal to Nmin=5. 
Estimating the “hit rate’’ as 0.6 and the per spectrum sensitivity and specificity as 81.8% 
and 96.3%, respectively, we obtained the predicted per segment 81.94% sensitivity and 
98.73% specificity. Using the number of non-BCC segments in the sample 
Nsampling,nonBCC=150, and the above per segment specificity estimate, the corresponding per 
sample specificity estimates was 95.65% when Nth=5. Using the above per segment sensitivity 
estimate and specifying, and considering the worst case scenario when the samples has single 
BCC segment (Nsampling,BCC=1), the corresponding per sample sensitivity was 11.03% when 
Nth=5. Being estimated for samples with a single BCC segment, these performance 
characteristics are overly pessimistic since BCC tumours typically spread over several 
segments in the AF image. For example, infiltrative BCCs typically consist of tens of 
microscopic (50-200μm) tumour regions. Thus, if we considered a more realistic case where 
the BCC is present in 10 segments, using Nth=5 leads to the per sample sensitivity and 
specificity of 99.93% and 95.65%, respectively.  
Note that any sample containing non-BCC segments can have amongst its NBCC detections 
false alarms. Thus, even if such a sample contains BCC segments and is diagnosed to be 
“BCC-positive” (NBCC≥Nth), this does not mean that all of its NBCC detections, nor even Nth of 
them, are necessarily true positive. In the extreme case a BCC sample can be diagnosed as 
BCC while all of its NBCC detections are false positives. In practice, however, a sensible 
statistical test will need to assure that the chance of this happening is negligible. Using our test 
on samples with a single BCC segment, however, this probability (of correctly identifying 
such a sample as BCC based entirely on false positive segments) is 15.40% when Nth=1, but 
reduces to 0.78% when Nth=5. When a sample with more than 10 BCC segments, the 
probability drops below 10-6. 
It is important to realise that all of the above calculations are based on simplifying 
assumptions, such as that of statistical independence of test outcomes from different 
segments, constant number of spectra per segment (and subsequently constant per segment 
performance characteristics).  Thus, the above predictions may be overestimates of the real 
performance. Nevertheless, the above calculations provide a simple guidance for selecting the 
threshold Nth in order to allow an objective way of establishing the diagnosis based on an 
MSH image. Further improvement of performance may be achieved by allowing the threshold 
Nth to depend on additional parameters of the sample, including those which have been 
assumed to be constant in the above discussion. 
3.2 Transferability of the algorithms on the automated MSH Prototype using independent 
samples  
After the optimisation of the MSH algorithms using the training set of samples measured on 
the Laboratory instrument, the algorithms were implemented on the fully automated 
Prototype. A set of 47 independent skin samples (of which 32 BCC positive) from 40 patients 
undergoing Mohs micrographic surgery was used to evaluate the performance of each step of 
the algorithm in order to assess the inter-instrument transferability.  
Figure 6(a) presents the analysed AF images of two typical skin samples containing BCC. 
The tumour regions have low AF intensity, and are correctly captured by the segmentation 
algorithms (ߩ = 0.64 and 0.65). The values of ߝ were 0.46 and 0.42, indicating that the 
segments containing BCC also contained ~60% healthy tissue.  
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Firstly, we tested the use of the threshold number Nth=5 that would allow a binary 
diagnosis of a skin sample as “BCC-positive” or “BCC-negative”. Sample 1 in Fig. 7 is an 
example of a skin sample with a large BCC of ~2mm. In this case, the number of segments 
labelled as BCC by the MSH algorithm was >20, which is higher than Nth, and the sample was 
diagnosed “BCC-positive”. Sample 2 had 10 tumour regions, ranging between 100 μm to 
1mm in size. Therefore, this sample is close to the detection limit of the instrument. The MSH 
analysis detected 8 BCC segments (6 true-positives and 2 false-positive segments), leading to 
the “BCC-positive” diagnosis. For the BCC-clear sample in Fig. 7 (Sample 3), the MSH 
diagnosis labelled 7 small segments as BCC. Because the number of segments labelled BCC 
is higher than the proposed threshold Nth=5, this sample was incorrectly diagnosed as “BCC-
positive” (false-positive). This result indicates that the predicted 95.65% specificity for the 
Nth=5 threshold is likely to be an over-estimation, and suggests that the assumptions used in 
the calculations were too simplistic (i.e. ignore the correlation between the spectra in the 
samples). In addition, the calculations for the Nth considered only the first round of Raman 
measurements. In the second round, additional Raman spectra are collected for segments that 
contained at least 2 but less than 80% spectra classified as BCC in the first round. If any of the 
Raman spectra in the second round are classified as BCC, but still do not reach the 80% 
threshold to label the whole segment as BCC, the initial segment is divided into smaller 
segment. Therefore, the second round of Raman measurements may lead to additional smaller 
false-positive segments in the final MSH image. This effect can be observed in Fig. 7: most 
false positive segments in Sample 3 are smaller in size than the true positive segments in 
Samples 1 and 2. To take into consideration these factors, a new threshold value was set at 
Nth=8. This new threshold would deliver the correct diagnosis for the samples presented in 
Fig. 7, and Sample 2 would represent a case at the limit of detection (8 segments labelled as 
BCC). Using the new threshold of Nth=8, our probabilistic model predicts to deliver 92.93% 
sensitivity and 99.93% specificity per tissue sample. 
Next, we evaluated the consistency of the MSH diagnosis by repeating the analysis three 
times on a set of three new samples. We included typical skin samples with large BCC 
(>4mm) and small BCC (e.g. 0.5-2 mm), and a BCC-clear sample. Each repeat measurement 
included the full analysis protocol: loading the tissue in the measurement cassette and loading 
the cassette into the instrument. At the end of the analysis, the cassette was unloaded from the 
instrument and the sample moved in a Petri dish. The stability of the Raman classifier was 
also evaluated by using different integration times for the Raman measurements (1s, 2s and 3s 
respectively). For Sample 1, >20 BCC segments were detected covering the area of the 
tumour, and 6-8 false positive segments were found at the edges of the sample (likely to 
correspond to inflamed dermis and hair follicles). Based on the Nth=8 threshold, correct BCC-
positive diagnosis was obtained for all repeat measurements. Sample 2 represented a sample 
at the limit of detection as it contained only two main BCC regions. One region had a tumour 
of ~1mm and few additional microscopic tumours, while the second region had a main tumour 
of ~1.5mm surrounded by 12 microscopic tumours (size 100-200μm). Nevertheless, the 
sample was correctly diagnosed as BCC-positive in all repeat measurements because the MSH 
image detected >12 BCC segments. 
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measurements to 2s and 3s led to longer analysis times (47-57 minutes and 72-78 minutes, 
respectively) but decreased the number of false positive segments. 
Finally, we evaluated the performance of the automated Prototype device when operated 
by non-specialist spectroscopy users. The MSH diagnosis obtained by two clinical users was 
compared to the result obtained by a spectroscopy specialist, as well as the reference 
histopathology. MSH is based on automated measurement and analysis algorithms, and the 
quantitative diagnosis is presented in a colour-coded image, in which each colour corresponds 
to a tissue class. The final diagnosis at a tissue level is obtained by comparing the number of 
BCC classified segments in the MSH image with a threshold value Nth. Because the actual 
tissue analysis is user-independent, the user requires training only on tissue handling (few 
hours). To demonstrate this feature, three users carried out repeat MSH analysis on a new set 
of skin specimens excised during Mohs micrographic surgery. User 1 (R. Boitor) was 
specialist in Raman spectroscopy and was the main person developing the MSH algorithms. 
User 2 (S. Varma) was a Mohs surgeon, and User 3 (B. Salence) was a core medical trainee 
intending to pursue a speciality in dermatology.  
 
 
 
Fig. 9. Consistency of MSH diagnosis among different users. User 1: spectroscopy specialist 
(R. Boitor), User 2: Mohs surgeon (S. Varma) with 1 h training, User 3 (B. Salence): core 
medical trainee with interest in dermatology (BS) with 8 hours training. Tumours are encircled 
in blue circles and false positive segments in Sample 3 are highlighted by black arrows (circles 
and arrows were added manually). 
  
User 2 and 3 had no experience in Raman spectroscopy and had ~1 hour, respectively 8 hours, 
training on tissue handling (load/unload tissue in cassette) and operation of the prototype 
instrument (load cassette in the instrument, input patient data, and start/stop analysis). 
Figure 9 presents the MSH results obtained by the three users, and compares the results 
with the reference histopathology slides. For the BCC-positive samples (Samples 1 and 2), the 
number of segments classified as BCC was higher than the threshold value Nth=8 for all 
measurements, leading to correct “BCC-positive” diagnosis. For the BCC clear sample 
(Sample 3) analysed independently by User 1 and User 3, the number of false positive 
segments was 7 and 5, respectively, indicating consistent “BCC-negative” diagnosis. These 
results highlight the advantage of MSH diagnosis in providing a reliable and quantitative 
diagnosis, even when the analysis was carried out by non-specialist users with training as 
short as 1 hour. This feature is important when considering the deployment of the technology 
in the clinic; non-specialist users can operate the devices and obtain valid and repeatable 
diagnosis of each resected tissue layer in order to confirm the completeness of tumour 
excision. This is a key advantage compared to conventional histopathology or alternative 
optical microscopy techniques based on structural imaging, where users require extensive 
training and experience in order to recognise specific structural and morphological features 
required for diagnosis. 
4. Conclusions 
In this paper we present a fully automated multimodal spectral histopathology (MSH) 
Prototype instrument for detection of residual tumor during surgery of basal cell carcinoma 
(BCC). The instrument has been designed to be used in a clinical environment and be 
operated by non-specialist users. First, the data acquisition and analysis algorithms were 
optimized on a manually-operated Laboratory instrument, and then successfully transferred on 
the automated Prototype. We demonstrate that accurate diagnosis of residual BCC can be 
obtained in an automated manner on a range of skin specimens excised during Mohs 
micrographic surgery. Typical acquisition times for tissue samples with areas of 2cm x 2cm 
was less than 60 minutes, allowing detection of tumors as small as 100 μm. Using a simple 
binary diagnosis protocol based on threshold number of BCC detected segments in the MSH 
images (Nth=8), the correct diagnosis was obtained for all samples, in three repeat 
measurements (confirmed by histopathology as the standard of reference). We also show that 
the instrument can be operated by non-specialist spectroscopy users, including one Mohs 
surgeon and one core medical trainee, after training in tissue handling and instrument 
operation of 1-8 hours training. The MSH diagnosis obtained by the non-specialist users was 
consistent with the results obtained by the spectroscopy specialist user, and agreed with the 
diagnosis provided by histopathology. This is an important result considering that the intended 
users of the device are histopathology technicians, nurses or dermatology surgeons. This is the 
first fully-automated prototype instrument based on Raman spectroscopy for intra-operative 
microscopic imaging of surgical margins during cancer surgery, suitable to be used by a non-
specialist user in a clinical environment. The development of the prototype is an important 
step on the clinical translation path, as it will allow the testing of the multimodal spectral 
histopathology technique in a relevant clinical environment in order to evaluate its 
performance on a sufficiently large number of patients. 
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